CANNDOC Pharma
Pharma-grade Cannabis Products
StartupCANNDOC Pharma is a Herzliya-based startup in the Health Tech & Life Sciences sector, established in 2008. Pharma-grade Cannabis Products. The company has 1-10 employees. Core technologies: Materials & Substances, Raw Materials, Biologicals, Genes.
The company follows a B2G/B2B business model. Product stage: Released. The company holds 1 patent. CANNDOC Pharma has been acquired.
- StageAcquired
- ProductReleased
- ModelB2G, B2B
- Employees1-10
- HQHerzliya
- DistrictCenter District
- StatusAcquired
- Last RoundUndisclosed
18 articles covered by sources including www.globenewswire.com,
www.bizportal.co.il,
www.newcannabisventures.com,
www.sponser.co.il,
www.newswire.ca.
What does CANNDOC Pharma do?
Canndoc is developing pharma-grade cannabis products. Over the years, Canndoc has provided more than 500,000 doses to 15,000 patients, demonstrating expertise across the value chain from research, cultivation, and processing to product development and good manufacturing practice (GMP) clinical trial pipeline initiation. Driven by the mission of meeting patients' needs and improving their quality of life, Canndoc's GMP-standard products are prescribed for a range of indications including neuropathic pain, pain from cancer, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures. Canndoc is a fully owned subsidiary of Israeli Medical Cannabis, Intercure. Its products and genetics cover European, Canadian, and Israeli regulatory requirements.
What sector is CANNDOC Pharma in?
CANNDOC Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Medical Cannabis, with core technologies in Materials & Substances, Raw Materials, Biologicals, Genes. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.
Where is CANNDOC Pharma located?
CANNDOC Pharma is based in Medinat HaYehudim Street 85, Herzliya, Israel, Center District.